BSc (Med), MBBS (Hons), FRACP, FRCPA, PhD
David Yeung is the head of haematology at the Royal Adelaide Hospital; Clinical Associate Professor at the Adelaide Medical School; and SA Cancer Council Beat Cancer Project Clinical Investigator at the South Australia Health and Medical Research Institute. David received his haematology and BMT training in Sydney, before completing his PhD studies in Adelaide on the optimal the use of tyrosine kinase inhibitors (TKI) as targeted therapy for chronic myeloid leukaemia (CML). David’s clinical research portfolio as principal investigator include several frontline TKI studies conducted through the Australasian Leukaemia and Lymphoma Group. With Prof Tim Hughes, A/Prof David Yeung leads one of the first trials to evaluate efficacy and safety of asciminib in newly diagnosed chronic phase CML. He is also the medical lead in a national project looking at genomics of high risk acute lymphoblastic leukaemia.